Back to Directory
Efinopegdutide
Metabolic & Weight ManagementGLP-1/Glucagon dual agonist with extremely long half-life for monthly dosing.
Key Benefits
- ✓Monthly dosing potential
- ✓Weight loss
- ✓Dual GLP-1/glucagon effects
- ✓Metabolic improvements
Dosing Information
Dosage Range
Under investigation
Frequency
Once monthly
Typical Duration
Development uncertain
Detailed Protocol
Designed for once-monthly subcutaneous injection. Clinical development faced setbacks and status uncertain.
About Efinopegdutide
Efinopegdutide is a PEGylated dual GLP-1/glucagon agonist with an exceptionally long half-life enabling once-monthly dosing. Phase 2 trials showed weight loss and metabolic benefits. Development by Hanmi/Sanofi faced setbacks.
Research Notes
Phase 2 trials showed efficacy but development partnership ended. Demonstrated feasibility of monthly dosing for dual agonists. Current status uncertain.
Potential Side Effects
- •Development setbacks
- •GI side effects
- •Status unclear
Always consult with a healthcare professional before starting any peptide therapy.